AIMS/HYPOTHESIS: We evaluated in a double-blind study the effect of early treatment with the immunomodulatory drug fusidin in patients with newly diagnosed type 1 diabetes mellitus. METHODS:Twenty-eight adults with newly diagnosed type 1 diabetes were included in the study. The patients were randomly assigned (computer-generated random number sequence) to two experimental groups. Patients allocated to the fusidin (FUS) group (n=15) received sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks). Subsequently the drug was given at the same dose and scheduled for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks. Subjects allocated to the placebo (PCB) group (n=13) received placebo according to the same schedule and conditions described for sodium fusidate in the FUS group. All patients received a diet adjusted to their age and BMI, and intensive insulin therapy. RESULTS: There were no statistically significant differences between the FUS and PCB groups in beta cell function, evaluated by basal and glucagon-stimulated C-peptide values during the follow-up (24 and 48 weeks). There was also no difference between the two groups in insulin requirement after 48 weeks (0.4+/-0.2 and 0.4+/-0.2 U/kg body weight for the FUS and PCB groups, respectively). Antibody titres, including insulin autoantibodies, were similar in the two groups during the follow-up. CONCLUSIONS/ INTERPRETATION: Early treatment of newly diagnosed type 1 diabetes patients with intermittently administered fusidin failed to influence the natural course of the disease.
RCT Entities:
AIMS/HYPOTHESIS: We evaluated in a double-blind study the effect of early treatment with the immunomodulatory drug fusidin in patients with newly diagnosed type 1 diabetes mellitus. METHODS: Twenty-eight adults with newly diagnosed type 1 diabetes were included in the study. The patients were randomly assigned (computer-generated random number sequence) to two experimental groups. Patients allocated to the fusidin (FUS) group (n=15) received sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks). Subsequently the drug was given at the same dose and scheduled for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks. Subjects allocated to the placebo (PCB) group (n=13) received placebo according to the same schedule and conditions described for sodium fusidate in the FUS group. All patients received a diet adjusted to their age and BMI, and intensive insulin therapy. RESULTS: There were no statistically significant differences between the FUS and PCB groups in beta cell function, evaluated by basal and glucagon-stimulated C-peptide values during the follow-up (24 and 48 weeks). There was also no difference between the two groups in insulin requirement after 48 weeks (0.4+/-0.2 and 0.4+/-0.2 U/kg body weight for the FUS and PCB groups, respectively). Antibody titres, including insulin autoantibodies, were similar in the two groups during the follow-up. CONCLUSIONS/ INTERPRETATION: Early treatment of newly diagnosed type 1 diabetespatients with intermittently administered fusidin failed to influence the natural course of the disease.
Authors: Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone Journal: N Engl J Med Date: 2002-05-30 Impact factor: 91.245
Authors: F Nicoletti; R Di Marco; I Conget; R Gomis; C Edwards; G Papaccio; K Bendtzen; S Sandler Journal: J Autoimmun Date: 2000-12 Impact factor: 7.094
Authors: F Nicoletti; A Nicoletti; S Giuffrida; R Di Marco; P Meroni; K Bendtzen; M Lunetta Journal: J Neurol Neurosurg Psychiatry Date: 1998-08 Impact factor: 10.154
Authors: F Nicoletti; P Zaccone; R Di Marco; G Magro; S Grasso; S Morrone; A Santoni; G Tempera; P L Meroni; K Bendtzen Journal: Immunology Date: 1995-08 Impact factor: 7.397
Authors: F Nicoletti; R Di Marco; S Morrone; P Zaccone; D Lembo; S Grasso; A Santoni; P L Meroni; K Bendtzen Journal: Immunology Date: 1994-02 Impact factor: 7.397
Authors: Y Mori; M Suko; H Okudaira; I Matsuba; A Tsuruoka; A Sasaki; H Yokoyama; T Tanase; T Shida; M Nishimura Journal: Diabetologia Date: 1986-04 Impact factor: 10.122